Faron Pharmaceuticals Ltd (LON:FARN) has hired experienced pharma executive Matti Karvonen as its new medical director as it expands its clinical activities.
Chief executive Dr Markku Jalkanen said his appointment came at an important time.
"Our lead drug candidate Traumakine, for the treatment of Acute Respiratory Distress Syndrome (ARDS) is now in a pan-European Phase III INTEREST trial, while clinical development for Clevegen, our novel cancer immunotherapy drug candidate is under active planning.
"Dr. Karvonen's experience in taking drugs through development programmes will provide an invaluable insight into the needs of both ARDS and cancer patients."
Karvonen has a background in clinical neurology and has worked with big names like Roche, Biogen Idec and Novartis. He has taken part in many clinical programmes, most recently in the pan-European launch of a new neurological drug.